医学診断法ジャーナル
オープンアクセス
ISSN: 2168-9784
ISSN: 2168-9784
Antonio Perez
The realisation, commercialization, and clinical use of nanoengineering, nanomedicine, and material science for drug delivery
are all becoming a reality. Nanomaterials must be developed carefully to assure physiological and biological compatibility before
they can be successfully integrated into nanotherapeutics. MSNs are appealing nanocarriers because of their biodegradable,
biocompatible, and somewhat pliable porous frameworks, which can be functionalized for better targeting and delivery in a
range of disease scenarios. To develop sterically stabilised, hydrophilic MSNs capable of efficient loading and delivery of the
hydrophobic anti-neoplastic medication, doxorubicin, an optimum formulation of an MSN with polyethylene glycol (2% and
5%) and chitosan was conducted (DOX). The anticancer, apoptotic, and cell-cycle effects of DOX-loaded MSNs in selected
cancer cell lines were examined, as well as the pH-sensitive release kinetics of DOX. MSNs ranging in size from 36 to 60
nm, with a pore diameter of 9.8 nm and a total surface area of 710.36 m2/g were created. The PCMSN formulation (2%
pegylated MSN) showed the highest DOX loading capacity (0.98 mgdox/mgmsn) and a 72-hour sustained release profile.
At concentrations of 20 g/mL-50 g/mL, pegylated drug nanoconjugates were successful in triggering death in cancer cells,
demonstrating their potential as drug delivery vehicles.